eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Special issues Subscription
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2009
vol. 5
 
Share:
Send email
Share:
abstract:

Combination of monoclonal antibody (Bevacizumab) and chemotherapy (FOLFIRI) in palliative treatment of metastatic adenocarcinoma of the small bowel (SBC): case report and review of the literature.

Rafał Stec
,
Bartłomiej Grala
,
Michał Mączewski
,
Lubomir Bodnar
,
Arkadiusz Zegadło
,
Cezary Szczylik

Arch Med Sci 2009; 5, 4: 647-651
Online publish date: 2009/12/30
View full text Get citation
 
Small bowel cancer (SBC) is very rare malignancy. Annually about only 89 new cases of SBC are diagnosed in Poland (0.1-0.3%) of all malignancies and approximately 1% of gastrointestinal cancers. The prognosis of metastatic SBC is rather poor. The median survival of patients undergoing chemotherapy is approximately 14 months. Small bowel cancer is considered refractory to chemotherapy. Various anticancer agents have been tested in palliative chemotherapy of SBC: 5-Fluorouracil (5-FU), Cisplatin, Adriamycin, Mitomycin C, Oxaliplatin, Irinotecan, Carboplatin. Here we report a rare case of metastatic SBC with complete response (CR) after combination treatment with monoclonal antibody (Bevacizumab) and FOLFIRI (5-FU, Leukovorin, Irinotecan). The patient is alive without disease progression 28 months after her primary presentation of SBC.
keywords:

small bowel cancer, chemotherapy, FOLFIRI, Bevacizumab
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.